Morgan Stanley
NRXP icon

Morgan Stanley’s NRX Pharmaceuticals NRXP Stock Holding History

Morgan Stanley’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$298K Buy
102,207
+61,306
+150% +$218K ﹤0.01% 5823
2026
Q2 		$167K Buy
40,901
+30,873
+308% +$102K ﹤0.01% 6033
2026
Q1 		$21.4K Sell
10,028
-1
-0% -$2 ﹤0.01% 6699
2025
Q4 		$27.2K Sell
10,029
-1,051
-9% -$2.82K ﹤0.01% 6600
2025
Q3 		$36.6K Buy
11,080
+6,684
+152% +$19.1K ﹤0.01% 6505
2025
Q2 		$14.3K Sell
4,396
-7,500
-63% -$18.8K ﹤0.01% 6760
2025
Q1 		$24.4K Buy
11,896
+7,500
+171% +$21.1K ﹤0.01% 6499
2024
Q4 		$9.7K Hold
4,396
– – ﹤0.01% 6816
2024
Q3 		$7.43K Hold
4,396
– – ﹤0.01% 6798
2024
Q2 		$10.7K Buy
4,396
+1
+0% +$4 ﹤0.01% 6661
2024
Q1 		$20.7K Sell
4,395
-38
-0.9% -$175 ﹤0.01% 6477
2023
Q4 		$20.4K Sell
4,433
-300
-6% -$991 ﹤0.01% 6443
2023
Q3 		$12.3K Hold
4,733
– – ﹤0.01% 6655
2023
Q2 		$22.9K Hold
4,733
– – ﹤0.01% 6527
2023
Q1 		$31.2K Sell
4,733
-301
-6% -$3.05K ﹤0.01% 6456
2022
Q4 		$55.9K Sell
5,034
-897
-15% -$9.04K ﹤0.01% 6246
2022
Q3 		$43K Buy
5,931
+294
+5% +$1.98K ﹤0.01% 6468
2022
Q2 		$33K Buy
5,637
+457
+9% +$6K ﹤0.01% 6800
2022
Q1 		$128K Sell
5,180
-554
-10% -$18K ﹤0.01% 6167
2021
Q4 		$274K Buy
5,734
+1,629
+40% +$118K ﹤0.01% 5891
2021
Q3 		$381K Buy
4,105
+118
+3% +$15.4K ﹤0.01% 5655
2021
Q2 		$463K Buy
3,987
+3,920
+5,851% +$1.03M ﹤0.01% 5570
2021
Q1 		$24K Sell
67
-69
-51% -$25K ﹤0.01% 6663
2020
Q4 		$33K Buy
+136
New +$22.3K ﹤0.01% 6290

Other funds holding NRXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Morgan Stanley's NRXP Position: Q3 2026 in Review

Morgan Stanley increased its NRX Pharmaceuticals (NRXP) stake by 150% in Q3 2026, buying an estimated $218K and bringing the position to 102,207 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #5823.

Morgan Stanley first reported a position in NRXP in Q4 2020 and has held it in 24 quarters since. The position peaked at $463K in Q2 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • Morgan Stanley held 102,207 shares of NRX Pharmaceuticals worth $298K as of Q3 2026.
  • Morgan Stanley bought 61,306 NRX Pharmaceuticals shares in Q3 2026, an estimated $218K.
  • NRX Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #5823 holding.
  • Morgan Stanley first reported a position in NRX Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Morgan Stanley's NRX Pharmaceuticals position peaked at $463K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.